Wockhardt Limited announced that two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food&Drug Administration (FDA).
QIDP status is granted to drugs which act against pathogens which have a high degree of unmet need in their treatment and are identified by the Centers for Disease Control. QIDP status allows for fast track review of the drug application by U.S. FDA, paving way for an early launch. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.
Dr. Habil Khorakiwala, Wockhardt Founder & Chairman said, "Globally there is a significant antibiotic vacuum due to dual impact of rise in new resistant pathogens and declining research in this area which causes over 50,000 deaths in USA and Europe combined despite having excellent healthcare services.
"The emerging world may as well be sitting on an antibiotic time-bomb ready to explode. Superficially the bacterial diseases can be divided in two categories, gram positive and gram negative and these pathogens have prevalence in both of them. Over the years Wockhardt has developed a strong anti-infective program which focuses on development of drugs which target this antibiotic gap in both gram positive and gram negative domains. These two drugs act against one of the globally rising class of pathogens MRSA (Methicillin-resistant Staphylococcus Aureus) which causes a range of diseases from the skin infection to severe respiratory infections.
"In case of severe infections like Hospital Acquired Pneumonia (HAP) current medical cure has a very limited reach causing a high unmet need and mortality. Both of these drugs are effective against MRSA and have shown potential in treatment of HAP. WCK 771 is an intravenous (IV) drug while WCK 2349 is a solid oral tablet, which is a significant positive for the drug development scenario as currently there is very little advance drug research in developing solid oral dosages. Most of the research is in developing intravenous drugs which requires significantly higher medical attention and increased rate of hospitalization wherein the chances of catching other infections is very high.
"In addition to the fast track review of its drug application, QIDP status also grants a 5 year extension to the drug patents in USA which is a major support for the commercial aspect of the drug. These drugs will be entering in their global Phase -3 clinical trials early next year."
Wockhardt started its Anti-infective program 17 years back in 1997 to focus on developing next generation antibiotics.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- War On Doping And The Hypocritical Treatment Of Lance Armstrong
- Peanut Consumption Decreases Mortality
- How Marijuana Use Affects People With Bipolar Disorder
- The New York Times On Drugs - Wrong, Naive Or Misleading?
- Avoid These 3 Risk Factors, Gain 13 Years Of Quality Life
- The Borexino Detector And Its Physics Results
- Olive Oil Destroys Cancer Cells
- "Let me explain exactly why you or your family member reacted as they did, why the test subjects..."
- "One guy runs a red light and is stopped and confesses. One guy runs a red light and says he didn't..."
- "To the author: Before you write a story and assert that the treatment of Lance Armstrong was hypocritical..."
- "Above the author writes: Leipheimer was only banned for six months, and out of season so he did..."
- "I worked in cycling during the Armstrong period. Lance Armstrong was banned from cycling not so..."
- Antidepressants linked to improved cardiovascular outcomes
- Bee Bailout: If dollars rule the world, why shouldn't bees be too big to fail?
- Antidepressants linked with improved cardiovascular outcomes
- How healthy is genetically modified soybean oil?
- Healthier males help infertile obese females conceive